Study concept and design: Spertus, Farkouh, Fuster, Cohen.
Acquisition of data: Wang, Magnuson, Farkouh, Cohen.
Analysis and interpretation of data: Abdallah, Wang, Magnuson, Spertus, Cohen.
Drafting of the manuscript: Abdallah, Wang, Cohen.
Critical revision of the manuscript for important intellectual content: Abdallah, Wang, Magnuson, Spertus, Farkouh, Fuster.
Statistical analysis: Wang, Magnuson.
Obtained funding: Farkouh, Fuster, Cohen.
Administrative, technical, or material support: Farkouh.
Study supervision: Fuster, Cohen.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Magnuson reports receipt of grant support from Abbott Vascular, AstraZeneca, Boston Scientific, Daiichi Sankyo, Edwards Lifesciences, Eli Lilly, and Medtronic. Dr Spertus reports receipt of grant support and consulting fees from Gilead and owns the copyrights to the Seattle Angina Questionnaire. Dr Farkouh reports receipt of grant support from Eli Lilly and other research support from Boston Scientific, Bristol-Myers Squibb, Cordis, Eli Lilly, and Sanofi-Aventis. Dr Cohen reports receipt of grant support from Abbott Vascular, AstraZeneca, Biomet, Boston Scientific, Edwards Lifesciences, Eli Lilly, Jannsen Pharmaceuticals, and Medtronic, and consulting fees from Abbott Vascular, AstraZeneca, Eli Lilly, and Medtronic. The other authors report no disclosures.
Funding/Support: This study was supported by grants (U01 01HL071988 and 01HL092989) from the National Heart, Lung, and Blood Institute (NHLBI). Cordis and Boston Scientific provided the stents; Eli Lilly provided abciximab and an unrestricted research grant; and sanofi-aventis and Bristol-Myers Squibb provided clopidogrel.
Role of the Sponsor: The industry sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and decision to submit manuscript for publication. The NHLBI did have a role in the design and conduct of the study (oversight of protocol development and the Data and Safety Monitoring Board [DSMB]).
Disclaimer: The views expressed in this article represent those of the authors and do not necessarily represent the official views of the sponsors.
Additional Contributions: We thank José Aceituno, MS, Saint Luke’s Mid America Heart Institute, Kansas City, MO, for preparation of graphics. Mr Aceituno was not compensated in association with his contribution to this article.